BioWorld

April 7, 2004

NPS Begins Teduglutide Pivotal Trial In Short-Bowel Syndrome

NPS Pharmaceuticals Inc. initiated a pivotal Phase III study for the orphan product teduglutide, a potential treatment for short-bowel syndrome. (BioWorld Today) Read More

With $50M Series B, Archemix Has Funding To Last Until 2007

'Blockbuster Vs. Niche' Mindset Can Limit Profits, Skew Research

Australia-Based Norwood Seeks IPO On London's AIM Exchange

Xenogen Plans Sales Force Expansion With IPO Filing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...